To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of including nanopore sequencing-based brain tumour methylome classification in the National Genomic Test Directory.

The Department funded the Cancer 2.0 initiative in 2021, delivered by Genomics England in close partnership with NHS England. The three-year programme demonstrated that nanopore sequencing-based brain tumour classification demonstrates significant promise for the National Genomic Test Directory. Full validation is required before full clinical implementation can be considered.

Other genomic testing for brain cancer is already included in the National Genomic Test Directory. This testing can be delivered using a range of technologies, including whole genome sequencing (WGS) or Next Generation Sequencing (NGS) technology, namely large cancer gene panels, to ensure that a patient receives the most appropriate genomic testing depending on their individual circumstances.

To date no application has been made to NHS England to evaluate nanopore sequencing-based brain tumour methylome classification. If an application were received, NHS England would assess the evidence in line with the Test Directory policy.